Formule 517 Tab 100 mg Tablet is a Health Canada–registered human drug (DIN 00495301) held by Alimentex Inc., containing Senna. Health Canada lists its status as Cancelled Post Market (status date 19 Jul 1999). Nexara Health has matched 23 registrations of Senna across 5 other regulated markets.
Health Canada registration
| DIN | 00495301 |
|---|---|
| Brand name | Formule 517 Tab |
| Active ingredient | Senna |
| Strength | 100 mg |
| Dosage form | Tablet |
| Route | Oral |
| Company | Alimentex Inc. |
| Status | Cancelled Post Market — 19 Jul 1999 |
| Class | Human |
| ATC | |
| AHFS | 92:01.00* ; See footnote |
| Regulator record | Health Canada DPD entry · Product monograph |
Senna registered in other markets
23 registrations of the same molecule in 5 national registries outside Canada (first 22 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| Czech Republic | Senna | — | 2CH-200CH | Gra | R | SUKL DLP |
| Iceland | Senease | Parlogis - óskráð lyf | 7,5 mg | töflur | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Senna | Parlogis - óskráð lyf | 7,5 mg | töflur | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Senokot | Lyfjaver - óskráð lyf | 7,5 mg | töflur | 0 | Lyfjastofnun lyfjaverdskra |
| Iceland | Senokot | Parlogis - óskráð lyf | 7,5 mg | töflur | 0 | Lyfjastofnun lyfjaverdskra |
| Netherlands | Senna | BOIRON (Messimy) | 4 DH t/m 60 DH#2 CH t/m 200 CH#6 K t/m 100.000 K#1 LM t/m 30 LM | Globuli | Uitsluitend apotheek of drogist | EU national register |
| Netherlands | Senna | BOIRON (Messimy) | 4 DH t/m 60 DH#2 CH t/m 200 CH#6 K t/m 100.000 K#1 LM t/m 30 LM | Uitsluitend apotheek of drogist | EU national register | |
| United Kingdom | Senna 12mg tablets | — | 0001 | NHS dm+d VMP | ||
| United Kingdom | Senna 15mg chewable tablets | — | 0001 | NHS dm+d VMP | ||
| United Kingdom | Senna 15mg tablets | — | 0001 | NHS dm+d VMP | ||
| United Kingdom | Senna 15mg/5ml granules | — | 0001 | NHS dm+d VMP | ||
| United Kingdom | Senna 2.5mg/5ml oral solution | — | 0001 | NHS dm+d VMP | ||
| United Kingdom | Senna 7.5mg tablets | — | 0001 | NHS dm+d VMP | ||
| United Kingdom | Senna 7.5mg/5ml oral solution | — | 0001 | NHS dm+d VMP | ||
| United States | OneLAX SENNA | Atlantic Biologicals Corp. | Syrup | listed | FDA NDC | |
| United States | OneLAX SENNA | Atlantic Biologicals Corp. | Syrup | listed | FDA NDC | |
| United States | OneLAX SENNA | Akron Pharma Inc. | Syrup | listed | FDA NDC | |
| United States | Senna | Rugby Laboratories | Solution | listed | FDA NDC | |
| United States | Senna | Atlantic Biologicals Corp. | Syrup | listed | FDA NDC | |
| United States | Senna | Precision Dose, Inc. | Syrup | listed | FDA NDC | |
| United States | Senna Laxative | PD-Rx Pharmaceuticals, Inc. | Tablet, Film Coated | listed | FDA NDC | |
| United States | Senna Tabs | Pharbest Pharmaceuticals, Inc. | Tablet, Film Coated | listed | FDA NDC |
See every manufacturer of Senna worldwide →
Regulator price references for Senna
Published list or reimbursement prices for Senna presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.
| Country | Product | Strength | Pack | Price | Type | Source | As of |
|---|---|---|---|---|---|---|---|
| Iceland | Senna | 7.5mg | pakki | 784.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Senease | 7.5mg | pakki | 784.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Senokot | 7.5mg | pakki | 816.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
| Iceland | Senokot | 7.5mg | pakki | 6,178.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Formule 517 Tab (DIN 00495301) marketed in Canada?
No. Health Canada lists DIN 00495301 as Cancelled Post Market as of 19 Jul 1999.
Who holds the Canadian licence for this product?
Alimentex Inc. is the company of record in the Health Canada Drug Product Database.
Is Senna registered outside Canada?
Yes — Nexara Health has matched 23 registrations in 5 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 00495301, status date 1999-07-19; national medicine registries: EU national register, FDA NDC, Lyfjastofnun lyfjaverdskra, NHS dm+d VMP, SUKL DLP; price sources: Lyfjastofnun lyfjaverdskra. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 00495301, status date 1999-07-19; national medicine registries: EU national register, FDA NDC, Lyfjastofnun lyfjaverdskra, NHS dm+d VMP, SUKL DLP; price sources: Lyfjastofnun lyfjaverdskra.
Health Canada Drug Product Database (DPD), DIN 00495301, status date 1999-07-19; national medicine registries: EU national register, FDA NDC, Lyfjastofnun lyfjaverdskra, NHS dm+d VMP, SUKL DLP; price sources: Lyfjastofnun lyfjaverdskra. Last reviewed 2026-09-17. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.